Adherex Technologies (ADH) Regains All Rights to ADH-1 and Will Continue Clinical Development
More News related to ADH
- Adherex (ADH) Announces 2 Presentations of ADH-1 Data at Annual Meeting
- Adherex Technologies (ADX) Initiates Phase I Combination Trials for Treatment of Melanoma
- Adherex Technologies (ADH) Regains All Rights to ADH-1 and Will Continue Clinical Development
- Receives FDA Orphan Drug Designation for Eniluracil in Liver Cancer
- ADH Receives Investigational New Drug 'IND' Clearance
More News related to GSK
- Trading Review for Vivus Inc. Issued by Beacon Equity
- Trading Overview for Sinobiopharma Inc. Issued by StockPreacher.com
- bioMerieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
- Unusual 11 Mid-Day Movers 11/16: SPEX, NLST, DRAM, XJT Higher; PARD, CRXX, CAEI, CHIO Lower
- Notable Analyst Rating Changes 11/16: COH, JWN, GNK, ESEA, SVA, YGE Upgraded; PARD, GPS, JCP, DLTR Downgraded
Adherex Technologies (AMEX: ADH) announced that the GlaxoSmithKline (NYSE: GSK) one-time option to license ADH-1 has expired unexercised. As a result, Adherex has regained all rights relating to ADH-1 and will continue with the clinical development of the compound. The license agreement with GSK relating to eniluracil remains unchanged.
Under the license agreement, Adherex maintains an exclusive license to eniluracil for all indications and GSK retains its options to buy back the compound at specific points in time during the drug's development. If GSK exercises any of its options for eniluracil, Adherex would receive development and sales milestone payments of up to US$120 million plus up to double digit royalties.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
